[Secondary cholangitis of the critically ill].

Z Gastroenterol

Zentrum für Innere Medizin II, Städtisches Klinikum Brandenburg GmbH, Brandenburg an der Havel, Germany.

Published: August 2019

Sclerosing Cholangitis of the Critically Ill (SC-CIP) is a relatively new entity within the spectrum of secondary cholangitis that develops in the wake of intensive care therapy with mechanical ventilation and catecholamine treatment. It is caused by ischemic or immunologic injury to small bile ducts that becomes self-aggravating and persists beyond the end of the intensive care stay. Early clinical and laboratory findings show acute cholangitis with elevated CRP, gamma GT, AP, and bilirubin. ERCP shows damaged intrahepatic bile ducts with irregular calibers and biliary casts. The following phase is chronic and oligosymptomatic. Still, all laboratory parameters will stay mildly elevated and ERCP and MRCP will show progressive loss of small bile ducts. Long-term prognosis is poor. Even with UDCA therapy, most patients will develop liver cirrhosis within months or years.

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0958-2843DOI Listing

Publication Analysis

Top Keywords

bile ducts
12
cholangitis critically
8
intensive care
8
small bile
8
[secondary cholangitis
4
critically ill]
4
ill] sclerosing
4
sclerosing cholangitis
4
critically ill
4
ill sc-cip
4

Similar Publications

BACKGROUND Obstructive jaundice is a common surgical issue caused by obstruction in the bile ducts, which can result from factors such as stones or cancers in the main bile duct. This study aimed to investigate the effects of carvacrol, a compound known for its strong antioxidant properties, on intestinal damage, liver damage, and bacterial translocation in an animal model of obstructive jaundice. METHODS The study utilized six groups of six Wistar Albino rats each.

View Article and Find Full Text PDF

Inhibin, β, which is also known as INHBA, encodes a protein that belongs to the Transforming Growth factor-β (TGF-β) superfamily, which plays a pivotal role in cancer. Gastrointestinal tract (GI tract) cancer refers to the cancers that develop in the colon, liver, esophagus, stomach, rectum, pancreas, and bile ducts of the digestive system. The role of INHBA in all GI tract cancers remains understudied.

View Article and Find Full Text PDF

Management of primary sclerosing cholangitis: Current state-of-the-art.

Hepatol Commun

December 2024

Division of Gastroenterology and Hepatology, Department of Medicine, The Autoimmune and Rare Liver Disease Programme, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

Article Synopsis
  • Primary sclerosing cholangitis is a chronic liver condition associated with inflammation and fibrosis of bile ducts, often linked to inflammatory bowel disease and increases the risk of cancer.
  • Current treatments mainly offer supportive care, as there are no effective medical therapies available and liver transplantation can prolong life but does not cure the disease.
  • Research is ongoing into new therapies aimed at slowing disease progression and alleviating symptoms, with improved trial designs focused on selecting appropriate patients and using better outcome measures to assess treatment effectiveness.
View Article and Find Full Text PDF

The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.

Hepatology

January 2025

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.

Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease characterized by the progressive destruction of intrahepatic bile ducts, leading to fibrosis, and potentially cirrhosis. PBC has been considered a prototypical autoimmune condition, given the presence of specific autoantibodies and the immune response against well-defined mitochondrial autoantigens. Further evidence supports the interaction of immunogenetic and environmental factors in the aetiology of PBC.

View Article and Find Full Text PDF

Apoptosis-Inducing and Proliferation-Inhibiting Effects of Doramectin on Mz-ChA-1 Human Cholangiocarcinoma Cells.

Int J Mol Sci

December 2024

State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China.

Cholangiocarcinoma is a malignant tumor that emerges in the intrahepatic or extrahepatic bile ducts. Doramectin (DOR), a third-generation derivative of avermectins (AVMs), is renowned for its low toxicity and high efficiency. However, no research has hitherto focused on the anti-cholangiocarcinoma effects of these drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!